{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:20:19Z","timestamp":1773922819322,"version":"3.50.1"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1097\/icl.0000000000000071","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T13:51:50Z","timestamp":1418219510000},"page":"72-76","source":"Crossref","is-referenced-by-count":20,"title":["Tumor Necrosis Factor-\u03b1 Inhibitors as a Treatment of Corneal Hemangiogenesis and Lymphangiogenesis"],"prefix":"10.1097","volume":"41","author":[{"given":"Giulio","family":"Ferrari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Bignami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Rama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-2-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000099253","article-title":"Immune privilege and angiogenic privilege of the cornea.","volume":"92","author":"Cursiefen","year":"2007","journal-title":"Chem Immunol Allergy"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1097\/01.ico.0000183485.85636.ff","article-title":". Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation.","volume":"25","author":"Cursiefen","year":"2006","journal-title":"Cornea"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08820530500509358","article-title":"Angiogenesis and lymphangiogenesis-implications for corneal immunity.","volume":"21","author":"Dana","year":"2006","journal-title":"Semin Ophthalmol"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1755-3768.2011.02312.x","article-title":"The association between corneal neovascularization and visual acuity: A systematic review.","volume":"91","author":"Bachmann","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/01.tp.0000185197.37824.35","article-title":". How effective is penetrating corneal transplantation Factors influencing long-term outcome in multivariate analysis.","volume":"81","author":"Williams","year":"2006","journal-title":"Transplantation"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00417-007-0684-4","article-title":". Bevacizumab (Avastin) eye drops inhibit corneal neovascularization.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":". Topical ranibizumab as a treatment of corneal neovascularization.","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1096\/fj.12-225185","article-title":". Vascular endothelial growth factor promotes anatomical and functional recovery of injured peripheral nerves in the avascular cornea.","volume":"27","author":"Pan","year":"2013","journal-title":"Faseb J"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"4034","DOI":"10.4049\/jimmunol.143.12.4034","article-title":"Evidence for the existence of two forms of membrane tumor necrosis factor: An integral protein and a molecule attached to its receptor.","volume":"143","author":"Luettig","year":"1989","journal-title":"J Immunol"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/385729a0","article-title":". A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.","volume":"385","author":"Black","year":"1997","journal-title":"Nature"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease.","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"R12-2-20210128","first-page":"1327","article-title":". Modulation of TNF-alpha-induced apoptosis in corneal fibroblasts by transcription factor NF-kappaB.","volume":"41","author":"Mohan","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/archsurg.133.5.558","article-title":"Revisiting the role of tumor necrosis factor alpha and the response to surgical injury and inflammation.","volume":"133","author":"Ksontini","year":"1998","journal-title":"Arch Surg"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1126\/science.8171316","article-title":"Unraveling function in the TNF ligand and receptor families.","volume":"264","author":"Beutler","year":"1994","journal-title":"Science"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1074-7613(00)80152-1","article-title":"Regulated commitment of TNF receptor signaling: A molecular switch for death or activation.","volume":"11","author":"Pimentel-Muinos","year":"1999","journal-title":"Immunity"},{"key":"R17-2-20210128","doi-asserted-by":"crossref","first-page":"9292","DOI":"10.1073\/pnas.88.20.9292","article-title":". The two different receptors for tumor necrosis factor mediate distinct cellular responses.","volume":"88","author":"Tartaglia","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.55782\/ane-2008-1720","article-title":"Pro-inflammatory cytokine TNF-alpha as a neuroprotective agent in the brain.","volume":"68","author":"Figiel","year":"2008","journal-title":"Acta Neurobiol Exp (wars)"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.cellsig.2010.01.010","article-title":"Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction.","volume":"22","author":"Park","year":"2010","journal-title":"Cell Signal"},{"key":"R20-2-20210128","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.cdd.4401189","article-title":"Tumor necrosis factor signaling.","volume":"10","author":"Wajant","year":"2003","journal-title":"Cell Death Differ"},{"key":"R21-2-20210128","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1084\/jem.175.2.323","article-title":". Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors.","volume":"175","author":"Aderka","year":"1992","journal-title":"J Exp Med"},{"key":"R22-2-20210128","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.1167\/iovs.08-2669","article-title":"Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding.","volume":"50","author":"Sakimoto","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1001\/archopht.118.12.1666","article-title":". Topical soluble tumor necrosis factor receptor type I suppresses ocular chemokine gene expression and rejection of allogeneic corneal transplants.","volume":"118","author":"Qian","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"R24-2-20210128","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1172\/JCI0216493","article-title":"Clinical use of TNF revisited: Improving penetration of anti-cancer agents by increasing vascular permeability.","volume":"110","author":"Lejeune","year":"2002","journal-title":"J Clin Invest"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"8424","DOI":"10.1074\/jbc.M606923200","article-title":". Regulation of NF-kappaB-dependent gene expression by the POU domain transcription factor Oct-1.","volume":"282","author":"dela Paz","year":"2007","journal-title":"J Biol Chem"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00109-004-0555-y","article-title":". Nuclear factor-kappaB: Its role in health and disease.","volume":"82","author":"Kumar","year":"2004","journal-title":"J Mol Med (Berl)"},{"key":"R27-2-20210128","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0022-3565(24)29632-4","article-title":"Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells.","volume":"297","author":"Mark","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"R28-2-20210128","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1177\/026765910101600110","article-title":". Comparison of tumor necrosis factor-alpha effect on the expression of iNOS in macrophage and cardiac myocytes.","volume":"16","author":"Sanders","year":"2001","journal-title":"Perfusion"},{"key":"R29-2-20210128","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s00395-008-0749-5","article-title":". TNF-alpha induced shedding of the endothelial glycocalyx is prevented by hydrocortisone and antithrombin.","volume":"104","author":"Chappell","year":"2009","journal-title":"Basic Res Cardiol"},{"key":"R30-2-20210128","first-page":"L57","article-title":"Tumor necrosis factor-alpha augments pulmonary arterial transendothelial albumin flux in vitro.","volume":"258","author":"Goldblum","year":"1990","journal-title":"Am J Physiol"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1182\/blood-2006-05-020875","article-title":". Tumor necrosis factor alpha (TNF-alpha) receptor-II is required for TNF-alpha-induced leukocyte-endothelial interaction in vivo.","volume":"109","author":"Chandrasekharan","year":"2007","journal-title":"Blood"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/jlb.55.3.410","article-title":". Macrophages and angiogenesis.","volume":"55","author":"Sunderkotter","year":"1994","journal-title":"J Leukoc Biol"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1097\/ICO.0b013e31812f6d14","article-title":"Yin and yang in cytokine regulation of corneal wound healing: Roles of TNF-alpha.","volume":"26","author":"Saika","year":"2007","journal-title":"Cornea"},{"key":"R34-2-20210128","first-page":"3493","article-title":". Sjogrens syndrome: Cytokine and Epstein-Barr viral gene expression within the conjunctival epithelium.","volume":"35","author":"Jones","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R35-2-20210128","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1076\/ceyr.19.3.201.5309","article-title":". Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogrens syndrome keratoconjunctivitis sicca.","volume":"19","author":"Pflugfelder","year":"1999","journal-title":"Curr Eye Res"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/ICO.0000000000000071","article-title":". Alkali burn to the eye: Protection using TNF-alpha inhibition.","volume":"33","author":"Cade","year":"2014","journal-title":"Cornea"},{"key":"R37-2-20210128","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1167\/iovs.12-10782","article-title":". Safety and efficacy of topical infliximab in a mouse model of ocular surface scarring.","volume":"54","author":"Ferrari","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R38-2-20210128","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1167\/iovs.06-1083","article-title":". Endogenous TNFalpha suppression of neovascularization in corneal stroma in mice.","volume":"48","author":"Fujita","year":"2007","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R39-2-20210128","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1167\/iovs.10-5548","article-title":". Critical role of TNF-alpha-induced macrophage VEGF and iNOS production in the experimental corneal neovascularization.","volume":"53","author":"Lu","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.2353\/ajpath.2006.050980","article-title":". Loss of tumor necrosis factor alpha potentiates transforming growth factor beta-mediated pathogenic tissue response during wound healing.","volume":"168","author":"Saika","year":"2006","journal-title":"Am J Pathol"},{"key":"R41-2-20210128","first-page":"819","article-title":"El Annan J, et al..","volume":"128","author":"Goyal","year":"2010","journal-title":"Evidence of corneal lymphangiogenesis in dry eye disease: A potential link to adaptive immunity Arch Ophthalmol"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1167\/iovs.03-1380","article-title":". Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival.","volume":"45","author":"Cursiefen","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1084\/jem.20091385","article-title":"VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis.","volume":"207","author":"Wuest","year":"2010","journal-title":"J Exp Med"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4049\/jimmunol.0903180","article-title":". Cutting edge: Lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation.","volume":"184","author":"Dietrich","year":"2010","journal-title":"J Immunol"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00417-007-0683-5","article-title":". Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation.","volume":"246","author":"Bock","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/S0002-9440(10)62355-3","article-title":". Spontaneous corneal hem- and lymphangiogenesis in mice with destrin-mutation depend on VEGFR3 signaling.","volume":"166","author":"Cursiefen","year":"2005","journal-title":"Am J Pathol"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"R118","DOI":"10.1186\/ar2326","article-title":". Increased lymphangiogenesis in joints of mice with inflammatory arthritis.","volume":"9","author":"Zhang","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"R48-2-20210128","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/092986707781745541","article-title":"Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players.","volume":"14","author":"Ji","year":"2007","journal-title":"Curr Med Chem"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00018-011-0848-6","article-title":"Macrophages are important mediators of either tumor- or inflammation-induced lymphangiogenesis.","volume":"69","author":"Ji","year":"2012","journal-title":"Cell Mol Life Sci"},{"key":"R50-2-20210128","first-page":"163","article-title":"Anti-TNF alpha therapy of rheumatoid arthritis: What have we learned Annu Rev I","volume":"19","author":"Feldmann","year":"2001","journal-title":"mmunol"},{"key":"R51-2-20210128","first-page":"1204","article-title":"Anti-cytokine antibodies for rheumatic diseases.","volume":"10","author":"Atzeni","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"R52-2-20210128","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.autrev.2008.11.003","article-title":". Treatment of rheumatoid arthritis with anti-TNF-alpha agents: A reappraisal.","volume":"8","author":"Caporali","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R53-2-20210128","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S0140-6736(12)60026-9","article-title":"Crohns disease.","volume":"380","author":"Baumgart","year":"2012","journal-title":"Lancet"},{"key":"R54-2-20210128","first-page":"47","article-title":"Cytokine therapies in Crohns disease: Where are we now and where should we go Inflamm Allergy Drug T","volume":"10","author":"Caprioli","year":"2011","journal-title":"argets"},{"key":"R55-2-20210128","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":". Tumor necrosis factor antagonist mechanisms of action: A comprehensive review.","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther"},{"key":"R56-2-20210128","first-page":"227","article-title":"Drug insight: Different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior Nat Clin Pract R","volume":"3","author":"Rigby","year":"2007","journal-title":"heumatol"},{"key":"R57-2-20210128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40259-013-0022-9","article-title":"TNF inhibition for ophthalmic indications: Current status and outlook.","volume":"27","author":"Rifkin","year":"2013","journal-title":"BioDrugs"},{"key":"R58-2-20210128","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.exer.2004.06.001","article-title":". Etanercept treatment in the endotoxin-induced uveitis of rats.","volume":"79","author":"Avunduk","year":"2004","journal-title":"Exp Eye Res"},{"key":"R59-2-20210128","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/1529-0131(200106)44:6<1411::AID-ART235>3.0.CO;2-O","article-title":". Etanercept therapy in children with treatment-resistant uveitis.","volume":"44","author":"Reiff","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R60-2-20210128","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","article-title":". Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.","volume":"45","author":"Smith","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R61-2-20210128","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/09273940600659393","article-title":". Etanercept (enbrel)-associated inflammatory eye disease: Case report and review of the literature.","volume":"14","author":"Taban","year":"2006","journal-title":"Ocul Immunol Inflamm"},{"key":"R62-2-20210128","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jcjo.2012.12.003","article-title":". Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.","volume":"48","author":"Ozdemir","year":"2013","journal-title":"Can J Ophthalmol"},{"key":"R64-2-20210128","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/archopht.126.5.734","article-title":". Infliximab therapy for aggressive mooren ulceration.","volume":"126","author":"Saw","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R65-2-20210128","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/ICO.0b013e3181d4fd5c","article-title":". Interstitial keratitis secondary to severe hidradenitis suppurativa: A case report and literature review.","volume":"29","author":"Alzaga Fernandez","year":"2010","journal-title":"Cornea"},{"key":"R66-2-20210128","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.preteyeres.2008.11.005","article-title":". Therapeutic monoclonal antibodies in ophthalmology.","volume":"28","author":"Rodrigues","year":"2009","journal-title":"Prog Retin Eye Res"},{"key":"R67-2-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/ICO.0b013e318271cc2a","article-title":"The effect of topical infliximab on corneal neovascularization in rabbits.","volume":"32","author":"Kim","year":"2013","journal-title":"Cornea"},{"key":"R68-2-20210128","doi-asserted-by":"crossref","first-page":"3874","DOI":"10.1167\/iovs.09-5003","article-title":". Differential role of tumor necrosis factor (TNF)-alpha receptors in the development of choroidal neovascularization.","volume":"51","author":"Jasielska","year":"2010","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R69-2-20210128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ajo.2004.09.058","article-title":"Regression of neovascular age-related macular degeneration following infliximab therapy.","volume":"139","author":"Markomichelakis","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R70-2-20210128","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/archopht.125.9.1221","article-title":"Intravitreal infliximab and choroidal neovascularization in an animal model.","volume":"125","author":"Olson","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R71-2-20210128","doi-asserted-by":"crossref","first-page":"5487","DOI":"10.1167\/iovs.08-3171","article-title":". Dual role of intravitreous infliximab in experimental choroidal neovascularization: Effect on the expression of sulfated glycosaminoglycans.","volume":"50","author":"Regatieri","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R72-2-20210128","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.exer.2006.07.007","article-title":". Inhibition of TNF-alpha reduces laser-induced choroidal neovascularization.","volume":"83","author":"Shi","year":"2006","journal-title":"Exp Eye Res"},{"key":"R74-2-20210128","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1089\/jop.2010.0031","article-title":". Regression of optic disc neovascularization in patients with Behcets uveoretinitis after infliximab therapy.","volume":"26","author":"Kawaguchi","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"key":"R75-2-20210128","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/112067210401400515","article-title":". Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease.","volume":"14","author":"Giansanti","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"R76-2-20210128","doi-asserted-by":"crossref","first-page":"7557","DOI":"10.1167\/iovs.12-11515","article-title":". Neutralization of ocular surface TNF-alpha reduces ocular surface and lacrimal gland inflammation induced by in vivo dry eye.","volume":"54","author":"Ji","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R77-2-20210128","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1167\/iovs.08-2372","article-title":". Efficient intraocular penetration of topical anti-TNF-alpha single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer.","volume":"50","author":"Ottiger","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Eye &amp; Contact Lens: Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:22:03Z","timestamp":1747182123000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00140068-201503000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/icl.0000000000000071","relation":{},"ISSN":["1542-2321"],"issn-type":[{"value":"1542-2321","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}